BDX — Becton, Dickinson and Company

Constructive but not euphoric. The August 6, 2026 Q3 FY2026 print beat on both lines ($4.98B revenue vs. $4.89B consensus; $3.23 adjusted EPS vs. $3.14) and management raised FY2026 adjusted EPS guidance to $12.62-$12.72, which powered the 21.62% three-month advance through 2026-09-13. But the tape has cooled: -3.12% over one month, -3.73% over one week, and RSI at 45.09 as of 2026-09-13. The sell-side is genuinely split - FMP's tally is 16 buy / 17 hold / 1 sell (a 'Hold' consensus) with a $186.88 average target and a wide $159-$210 range, while the research brief frames it as a 'Buy' among 14-15 analysts. That gap is the sentiment in one line: investors like the post-spin margin story, but nobody is pounding the table at 92% of the 52-week high with a mass-tort MDL still open.

Revenue ran $5.09B (Q4 FY23) -> $4.71B (Q1 FY24) -> $5.05B (Q2 FY24) -> $4.99B (Q3 FY24) -> $5.44B (Q4 FY24) -> $5.17B (Q1 FY25) -> $5.27B (Q2 FY25) -> $5.51B (Q3 FY25) -> $5.89B (Q4 FY25), then stepped down to $5.25B (Q1 FY26), $4.71B (Q2 FY26) and $4.98B (Q3 FY26) - YoY changes of +1.6%, -10.6% and -9.5% in the last three quarters. That is not demand destruction; it is the February 2026 spin/combination of Biosciences and Diagnostic Solutions with Waters. On a continuing-ops basis the brief reports Q3 FY26 revenue up 5.4% YoY with a consensus beat, so the underlying franchise is mid-single-digit growing. The mix shift is real and favorable: gross margin climbed from 33.4% in Q4 FY23 to 46.5% in Q3 FY26 as lower-margin diagnostics left the portfolio. Operating margin is noisier - 6.9% (Q4 FY23), 14.6% (Q2 FY24), 16.0% (Q3 FY25), 13.3% (Q3 FY26) - with Q2 FY26 collapsing to 2.0% on a one-off charge that produced a -$311M net loss and -$1.11 diluted EPS. TTM revenue $20.84B, TTM operating margin 9.8%, TTM net margin 4.5%, all understated by that charge. Verdict: stable-to-improving underlying growth and margins masked by a structural reset and a one-time charge; reported comparability only normalizes from FY2027. Free cash flow has held up better than income - TTM $2.61B vs. FY2025's $2.67B, on a materially smaller asset base - while long-term debt was paid down from $17.6B (Sep 2025) to $13.5B (Jun 2026).

Split personality, and the gap is the whole story. Trailing GAAP numbers scream expensive: P/E TTM of 53.57 against a 5-year average of 31.02, net margin 4.5%, ROIC 4.7%, ROE 6.6% - which is why the deterministic overlay labels it 'Rich vs. its own history.' But that trailing P/E belongs to a company that no longer exists (pre-spin mix, plus the Q2 FY26 charge). On forward adjusted EPS of $12.67 - management's FY2026 guidance midpoint and the consensus figure in the dataset - BDX trades at 14.0x, below its own 5-year average and below the 15-18x large-cap medtech norm. P/S of 2.35 is also below the 5-year average of 2.63. Cross-checks agree: 5.3% FCF yield on $2.61B TTM free cash flow, and EV/EBITDA of 16.7x on reported TTM EBITDA of ~$3.70B, falling to ~14.7x on charge-normalized EBITDA of roughly $4.2B. Net read: cheap-to-fair on forward adjusted earnings and cash flow, expensive on trailing GAAP. Anyone running a screen on the 53.6x P/E is looking at a mirage; anyone valuing the forward franchise gets a mid-teens multiple on a 0.258-beta defensive with a 2.2-2.4% dividend.

As of 2026-09-13 the $177.85 price is doing two things at once. It is pricing in a recovery that has only partially shown up in reported GAAP numbers - forward adjusted EPS of $12.67 versus TTM GAAP EPS of $3.42 - so the 'P/E of 53' crowd and the '14x forward' crowd can both be right and mean opposite things. It is also pricing in most of the operational recovery already: the stock has re-rated 21.62% in three months ahead of what should be the first clean 'New BD' fiscal year, so the easy money from the guidance raise has largely been made. What is NOT priced in: any meaningful credit for the GLP-1/self-injection delivery tailwind (Vystra pen partnerships, the $110M Neopak prefillable-syringe capacity build in Columbus, Nebraska), or for further margin expansion under BD Excellence. What is also under-priced: the PowerPort MDL tail, where a $40M compensatory verdict has already landed and no global settlement is in the numbers. Practical read: the market is paying roughly fair value for a mid-single-digit grower; you are not buying a mispriced asset, you are buying the FY2027 guidance event and the litigation outcome.

As of 2026-09-13, RSI(14) was 45.09 - dead neutral, no oversold edge and no overbought risk. Price was 4.13% below the 20-day SMA (a short-term pullback), but 3.43% above the 50-day and 10.91% above the 200-day, so the medium and long-term trend structure is intact and upward. Returns: +21.62% over three months, +11.60% over six months, but -3.12% over one month and -3.73% over one week. The 52-week range is $127.59-$193.07, putting the stock at roughly 92% of its high and 39% off its low. Read: a healthy uptrend taking a breather, not a breakdown. There is no timing urgency here - a retest of the 50-day (roughly the $172 area) would offer a meaningfully better risk point than chasing at $177.85, and a decisive break below the 200-day (near $160) would signal the post-spin re-rating has stalled.

• Rate environment: beta of 0.258 makes BDX behave like a defensive quasi-bond-proxy, so falling long rates support the multiple - but $13.5B of long-term debt (net debt ~$12.8B, ~3.5x TTM EBITDA) makes refinancing costs a live sensitivity if rates back up.
• Tariffs and medtech supply-chain costs: the brief flags ongoing tariff pressure and procurement dynamics in key international markets like China; the $110M Columbus, Nebraska Neopak syringe investment is a reshoring hedge against that exposure.
• GLP-1/obesity drug boom: a structural tailwind, not a headwind, for BD - it manufactures the pen needles, prefillable syringes and auto-injector platforms (Vystra) that self-injection therapies require.
• Hospital capital spending and procedure volumes: BD's consumables-heavy device mix (vascular access, injection, surgery) tracks utilization more than capital budgets, which is a relative advantage if hospital capex slows.
• Post-Waters medtech portfolio simplification wave: the diagnostics/biosciences spin is part of a broader sector rotation toward higher-margin pure-plays, which affects how the market values the remaining 'New BD' asset base.

• Fiscal Q4 and full-year FY2026 earnings plus initial FY2027 guidance, expected early-to-mid November 2026 - the first clean, fully comparable 'New BD' year and the single biggest swing factor for the forward multiple.
• GalaFLEX LITE STANCE clinical trial updates and the FDA review path in tissue regeneration.
• Commercial ramp of recently launched devices - the Elyra Thulium Fiber Laser system and CentroVena One insertion system.
• Continued deleveraging (long-term debt already down $4.1B from Sep 2025 to Jun 2026) and further dividend growth on the current $1.05/quarter payout (ex-dividend September 9, 2026, payable September 30).
• Resolution or escalation of the C.R. Bard PowerPort MDL - a global settlement would remove a live overhang; adverse verdicts would compound it.

• PowerPort MDL litigation: the recent $40M compensatory verdict is small relative to a $49B market cap, but implantable-port mass torts have a history of expanding, and no settlement reserve appears to be guided.
• Weak trailing profitability and returns: ROIC of 4.7%, ROE of 6.6%, net margin of 4.5% - the 14x forward multiple is a bet on adjusted EPS arriving, and adjusted EPS is not what the company reports at the bottom line.
• Balance-sheet liquidity: current ratio of 0.865, quick ratio of 0.513, and only $708M of cash against $9.4B of current liabilities. Manageable given ~$2.6B of annual free cash flow, but there is no cushion if cash generation slips.
• Post-spin execution and dis-synergies: the deterministic score's growth leg is registering a real -9% to -10% YoY revenue trend; even if most of it is the divestiture, some of the revenue and cost scale lost in the Waters transaction is permanent.
• International headwinds: China procurement dynamics, tariffs and FX can absorb 1-2 points of reported growth in a company that derives a large share of revenue outside the U.S.
• Valuation unwind risk: after a 21.62% three-month move into 2026-09-13, a soft FY2027 guide in November would have plenty of room to give back.

Not a buy with conviction at $177.85 as of 2026-09-13. The business is better than the deterministic score says and worse than the 14x forward multiple implies - post-spin BD is a mid-single-digit grower with 46.5% gross margins, ~$2.6B of free cash flow, a 2.2-2.4% dividend and a 0.258 beta, but it also carries ~$12.8B of net debt, a 0.865 current ratio, 4.7% ROIC, and an open-ended PowerPort MDL. The problem is timing and price, not quality: the stock has already re-rated 21.62% in three months on the guidance raise, RSI of 45.09 offers no oversold entry, and the trailing P/E of 53.57 against a 5-year average of 31.02 gives the market an easy excuse to sell any disappointment. Wait for either the FY2027 guidance in November 2026 or a pullback toward the 50-day near $172 before committing new capital.

I applied 15.0x to forward adjusted EPS of $12.67 (management's FY2026 guidance midpoint and the consensus figure in the dataset) - a discount to the 15-18x large-cap medtech range to reflect the PowerPort MDL tail, ~3.5x net debt/EBITDA and the 0.865 current ratio - which yields $190. I cross-checked that against a 5% required FCF yield on $2.61B of TTM free cash flow ($189/share on ~275.5M shares) and a 15.2x multiple on charge-normalized EBITDA of ~$4.2B ($197/share), then applied a ~2% haircut for the litigation and liquidity tail, landing at $186 as of 2026-09-13 - roughly 4.6% above the $177.85 price, and notably below the $210 high-end sell-side target.